IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") announced the execution of a Research Grant Agreement with Karolinska Unive...
As artificial intelligence (AI) and machine learning is commoditized, data becomes an enterprise's competitive advantage. Accessing high-quality data is ex...
Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more tha...
“Tislelizumab is the first medicine to come from BeiGene’s immuno-oncology research program and our team partnered with patients, caregivers, a...
Novel antibody specifically designed for oral administration utilizes Tillotts Pharma’s sustained release approach to ensure optimal and local trea...
PromoExQ MSC Growth Medium XF enables the long-term expansion of a variety of MSC types, including MSCs from the bone marrow, umbilical cord matrix, and ad...
Announced that the first patient has been injected in a Phase 1/2 study evaluating NBTXR3 activated by radiation therapy in combination with anti-PD-1/L-1 ...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon p...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the expansion of its digital PCR (dPCR) offering for the development of cell and gene th...
Through this collaboration, the companies aim to identify novel molecules that promote precise delivery of nucleic acid by leveraging Eleven's innova...
Endo International plc (OTC: ENDPQ) and Premier, Inc. (NASDAQ: PINC) announced today that Endo's Par Sterile Products business will supply Pitocin® (ox...
Join us for an in-depth conversation with Chua Keng Hock as we explore the challenges, strategies, and future prospects of the biopharma industry in today'...
Phase III OCARINA II trial met primary and secondary endpoints OCREVUS twice a year, 10-minute injection has the potential to further improve the treatm...
Target of 339 patients enrolled has been met in the SPARTA clinical trial, designed to evaluate efficacy and safety of two separate weekly doses of Grifo...
© 2025 Biopharma Boardroom. All Rights Reserved.
